High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme

María Apellániz-Ruiz(Navarrabiomed), Cristina Rodríguez‐Antona(Instituto de Salud Carlos III), Aguirre A. de Cubas(Medical University of South Carolina), Ahmed Rebaï(Centre of Biotechnology of Sfax), Adrián LLerena(Instituto de Salud Carlos III), Patricia Taboada-Echalar(University of Chile), Manuela Grazina(University of Coimbra), Lara M. Munín Sánchez(Spanish National Cancer Research Centre), Giuseppe Opocher(University of Padua), Graciela Moya(Pontificia Universidad Católica Argentina), Mercedes Robledo(The University of Texas at San Antonio Health Science Center), Soumaya Triki(Centre of Biotechnology of Sfax), Veronika Mančíková(Centro de Biología Molecular Severo Ochoa), Ángel Carracedo(Center for Research in Molecular Medicine and Chronic Diseases), Lucía Inglada‐Pérez(Spanish National Cancer Research Centre), Mahmood Rasool(King Abdulaziz University), Alberto Cascón(Spanish National Cancer Research Centre), Iñaki Comino‐Méndez(Breast Cancer Now), María Currás-Freixes(Spanish National Cancer Research Centre), M.E.G. Naranjo(Universidad de Extremadura), Magnus Ingelman‐Sundberg(Karolinska Institutet)
The Pharmacogenomics Journal
October 28, 2014
Cited by 67


Related Papers